SEC Form 4 · accession 0001682852-26-000131
Moderna, Inc. · MRNA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Soria Ester Banque
Officer — Chief Commercial Officer
Period of report
Jul 5, 2026
Accepted (ET)
Jul 7, 2026 · 4:25 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001682852
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $79.76 | Jul 5, 2026 | A | 18,658 | A | — | Jul 5, 2036 | Common Stock | 18,658 | 18,658 | D |
| Restricted Stock UnitsF2,F3 | — | Jul 5, 2026 | A | 38,364 | A | — | — | Common Stock | 38,364 | 38,364 | D |
Explanation of responses
- F125% of this option will vest and become exercisable on July 5, 2027 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
- F2Restricted stock units convert into common stock on a one-for-one basis.
- F325% of the shares subject to this restricted stock unit award will vest on July 5, 2027 with the remainder vesting in twelve (12) equal quarterly installments thereafter.